Yue Da Intl (00629) subsidiary enters into reverse factoring agreement with Dongtai Haoyao.
YueDa International Holdings Limited (00629) announced that on July 23, 2026, its indirect wholly-owned subsidiary, YueDa Commercial Factoring, entered into a reverse factoring agreement with Dongtai Houyao. Under the reverse factoring agreement, YueDa Commercial Factoring agreed to provide Dongtai Houyao with accounts receivable financing, accounts receivable management services, and accounts receivable collection services, and granted a reverse revolving credit limit of RMB 30 million, with an annual interest rate and factoring management fee totaling 6.5% to 7.2%. The agreement will take effect on July 23, 2026, and will expire on September 30, 2027.
YUE DA INTL (00629) announced that on July 23, 2026, its indirectly wholly-owned subsidiary YUEDA Commercial Factoring entered into a reverse factoring agreement with Dongtai Haoyao. Under the agreement, YUEDA Commercial Factoring agreed to provide accounts receivable financing, accounts receivable management services, and accounts receivable collection services to Dongtai Haoyao, and granted a reverse revolving credit limit of RMB 30 million. The annual interest rate and factoring management fee together are 6.5% to 7.2%. The agreement will be effective from July 23, 2026, and will expire on September 30, 2027.
Related Articles

ARCHOSAUR GAMES (09990) cancelled the repurchase of 3.009 million shares on July 23rd.

Grand Pharma (00512) is exploring the innovative track of traditional Chinese medicine treatment for depression with a goal of achieving billions in revenue. The first patient has been enrolled in the domestic Phase III clinical trial of GPN01360.

VIRSCEND EDU (01565) spent 1.2032 million Hong Kong dollars to repurchase 6.2 million shares on July 23.
ARCHOSAUR GAMES (09990) cancelled the repurchase of 3.009 million shares on July 23rd.

Grand Pharma (00512) is exploring the innovative track of traditional Chinese medicine treatment for depression with a goal of achieving billions in revenue. The first patient has been enrolled in the domestic Phase III clinical trial of GPN01360.

VIRSCEND EDU (01565) spent 1.2032 million Hong Kong dollars to repurchase 6.2 million shares on July 23.

RECOMMEND





